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RRT  renal replacement therapy 
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ABSTRACT 
Introduction 
Children often merit priority in access to deceased donor kidneys by organ-sharing 
organizations. We report the impact of the new Swiss Organ Allocation System 
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(SOAS) introduced in 2007, offering all kidney allografts from deceased donors<60 
years preferentially to children.  
Methods  
The retrospective cohort study included all paediatric transplant patients (< 20 years 
of age) before (n=19) and after (n=32) the new SOAS (from 2001-2014). Estimated 
glomerular filtration rate (eGFR), urine protein to creatinine ratio (UPC), need for 
antihypertensive medication, waiting times to kidney transplantation (KTX), number 
of pre-emptive transplantations and rejections, and the proportion of living donor 
transplants were considered as outcome parameters. 
Results 
Patients after the new SOAS had significantly better eGFRs 2 years after KTX (Mean 
Difference, MD=25.7 ml/min/1.73m2, P=0.025), lower UPC ratios (Median Difference, 
MeD=-14.5 g/mol, P=0.004), decreased waiting times to KTX (MeD=-97 days, 
P=0.021) and a higher proportion of pre-emptive transplantations (Odds Ratio=9.4, 
95%CI=1.1-80.3, P=0.018), while the need for antihypertensive medication, number 
of rejections and living donor transplantations remained stable.  
Conclusion  
The new SOAS is associated with improved short-term clinical outcomes and more 
rapid access to KTX. Despite lacking long-term research the study results should 
encourage other policy makers to adopt the SOAS approach. 
 
INTRODUCTION 
Kidney transplantation (KTX) is considered as the best treatment option for children 
and adults with end-stage renal disease [1]. The steadily increasing number of renal 
transplant candidates challenges the relatively unchanged kidney donor pool [2-4]. 
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Children with end-stage renal disease represent a numerical minority and can suffer 
from long-term effects on growth, and physical and cognitive development [5-8]. To 
address these issues, most organ-sharing organizations have developed specific 
allocation strategies for children [9-11]. Prior to the new Swiss Organ Allocation 
System (SOAS), kidney allograft allocation was based only on the factor time spent 
on the waiting list. The new SOAS was established to offer all renal allografts from 
deceased donors < 60 years preferentially to AB0-compatible children and young 
adults (< 20 yrs) aiming to reduce waiting time on the list for paediatric patients. Only 
patients in need of urgent KTX due to imminent lack of access to any mode of 
dialysis are preferred over children and young adults. Furthermore, the new SOAS 
provides the opportunity to place children on the waiting list without prior dialysis if 
the estimated glomerular filtration rate (eGFR) is < 15 ml/min per 1.73m2.  
We carried out a retrospective multicentre cohort study in all patients undergoing 
deceased donor KTX from 2001 to 2014 at Swiss paediatric nephrology transplant 
centres. The study objective was the assessment of the short-term clinical outcome 
of kidney transplants in children determined by eGFR, urine protein to creatinine 
(UPC) ratio, need for hypertensive medication, time spent on the transplant list, 
number of pre-emptive transplantations and rejections, and the proportion of living 
donor transplants. 
 
METHODS 
A retrospective multicentre cohort study was conducted by reviewing data from the 
Swiss Paediatric Renal Registry (SPRR) [12]. The registry contains demographic 
and clinical data for each patient dialysed and/or transplanted during childhood and 
adolescence in Switzerland since the introduction of renal replacement therapy 
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(RRT) in 1970. This study includes the SPRR data for all patients undergoing 
primary deceased donor KTX from 2001 to 2014 at paediatric nephrology transplant 
centres. Informed consent was obtained from the parents and/or from adolescent 
patients. 
Inclusion criteria for patients were defined as follows: < 20 years of age at time of 
deceased donor KTX. The study cohort was separated into two groups: patients 
transplanted from January 2001 – June 2007 were compared with those after the 
implementation of the new SOAS (July 2007 – June 2014). Patients placed on the 
transplant list before the new SOAS but transplanted afterwards were excluded due 
to the possible bias on patient characteristics such as waiting time. All patients 
received only transplants from ABO-compatible and heart-beating donors. 
Demographic and clinical characteristics were collected for both groups, such as 
sex, age, ethnic group, blood group, primary diagnosis, duration and modality of 
dialysis (haemodialysis or peritoneal dialysis), and time on dialysis. The primary 
diagnosis was classified according to one of the three specified categories: 
Congenital anomalies of the kidney and urinary tract, hereditary or acquired renal 
disorder [12]. Also, donor-related demographic and clinical characteristics were 
obtained such as age, body mass index, duration of cardiopulmonary reanimation, 
catecholamine administration, hypertension history, diabetes mellitus, cause of 
death, and data on last available creatinine, C-reactive protein and UPC ratio in the 
first morning spot urine.  
Quality characteristics of the transplant included data on ethnicity match, number of 
HLA mismatches, cold ischemia time (CIT), peak panel reactive antibodies (PRA) 
and immunosuppressive treatment regimen. This maintenance regimen consisted of 
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calcineurin-inhibitor (CNI; cyclosporine A or tacrolimus) combined with either 
mycophenolate mofetil (MMF) or azathioprine with or without induction therapy but 
corticosteroid administration for at least 12 months. 
The following clinical and laboratory data were collected for each patient on the first 
out-patient clinic appointment and one and two years after KTX: plasma creatinine 
(µmol/l), body weight (kg) and height (cm), antihypertensive medication (aiming for a 
24-hour blood pressure target < 95th percentile or < 50th percentile if proteinuria is 
present), and measurement of UPC ratio in the first morning spot-urine at last follow-
up. Estimated GFR was calculated using the Schwartz-formula method [13]. 
Diagnosis of rejection was made by a kidney biopsy either routinely performed (6 
months after KTX) or following clinical indication based on the available Banff 
classification or previously used classification systems [14, 15].  
The primary outcome measure was the eGFR (ml/min per 1.73m2 body surface) one 
and two years after KTX. Amount of proteinuria, number of patients with 
hypertension medication, time on waiting list (days), number of pre-emptive 
transplantations and rejections, and the proportion of living donor transplants were 
considered as secondary outcome measures. 
Demographic, disease-related and transplant-related variables were described using 
frequencies and percentages for categorical variables and mean ± standard 
deviation (normally distributed) or median and range (not normally distributed) for 
continuous variables. Group differences were assessed with Pearson’s chi-squared 
test for categorical variables and with independent sample t-test or Mann-Whitney 
test for continuous variables. The effect of the new SOAS on eGFR was analysed in 
a linear mixed effects model with random intercepts per subject and the following 
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baseline adjustment variables: follow-up time point, age at KTX, donor age, 
immunosuppressive treatment therapy, pre-transplant dialysis time, waiting time in 
the transplant list, UPC ratio at last follow-up, number of HLA mismatches and 
rejection. Comparison of the model with and without the effect in question was 
carried out by likelihood ratio tests, thereby obtaining a P-value for the effect. All data 
analyses were conducted using R 3.1.2 with the additional packages lmer4 1.1-10 
and rms 4.5-0 [16-18].  
 
RESULTS  
In total, 51 patients fulfilled the inclusion criteria, with 19 receiving KTX before and 
32 after the new SOAS. Basic demographic and clinical characteristics were similar 
for patients undergoing deceased donor KTX before and after the new SOAS, as 
shown in Table 1. Significant differences between groups were only found in the pre-
transplant dialysis time, which was significantly decreased after the new SOAS, from 
a median 555 days to 148 days (median difference MeD=-407days, P=0.006). 
Corresponding donor characteristics were comparable for both groups (Table 2) and 
revealed no significant differences except for an increase in donor age (mean 
difference MD=9.3years, P=0.040). The only difference regarding transplant 
characteristics was the type of combination immunosuppression therapy, with a 
significant shift towards CIN/MMF (odds ratio OR=14.3, 95%CI=1.7-121.8, P=0.013). 
We excluded 9 patients (4 before and 5 after the new SOAS) for the following 
reasons: graft loss as a consequence of hyperacute rejection and vascular 
thrombosis (n=2), loss of follow-up (n=3), recurrence of primary underlying disease 
(n=1) and death due to sepsis (n=3) < 1 year after KTX. Two additional patients were 
excluded due to listing before, but transplantation after the new SOAS. Excluded 
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patients did not show differences in recipient characteristics compared to those 
included for analysis regarding sex (p=0.212), mode of dialysis (p=0.055), blood 
group (p=0.559), age at KTX (p=0.378), ethnicity (p=0.105) and etiology of renal 
disease (p=0.217). They were not included in the analysis due to missing data for the 
primary outcome and the majority of secondary outcomes.  
 
Detailed results for the comparison of primary and secondary outcome measures be-
tween patients before and after the new SOAS are presented in Table 3. Estimated 
GFR showed significant differences at 1 year (MD=24.1ml/min per 1.73m3, P=0.013) 
and 2 years (MD=25.7ml/min per 1.73m3, P=0.025) after KTX, with increased mean 
values after the policy change. Also, patients after the new SOAS had lower UPC 
ratio levels (MeD=-14.5g/mol, P=0.004), a shorter median time spent on the KTX 
waiting list (MeD=-97days, P=0.021, see Figure 1), and a higher proportion of pre-
emptive transplantations (5% vs. 34%, OR=9.4, 95%CI=1.1-80.3, P=0.018). More 
than half of the patients needed antihypertensive medication after KTX, but this did 
not differ between groups. The number of rejections was not significantly different 
between both groups. Patients with routinely performed kidney biopsy 6 months after 
KTX did not necessarily have clinical signs of rejection or underwent therapy for 
rejection. 
 
The comparison of living donor proportions among all transplantations carried out in 
the study period revealed a non-significant trend towards a lower number of living 
donor transplants after the new SOAS (OR=0.5, 95%CI=0.2-1.0, P=0.052). Linear 
mixed effect modelling was applied to detect the influence of the new SOAS on 
eGFR, given a set of baseline covariates. We found a significant effect of the new 
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law (χ2(1)=15.129, P=0.0001), increasing the eGFR by 45.4 ml/min per 1.73m2 
(95%CI=24.5-66.3 ml/min per 1.73m2).  
 
DISCUSSION 
Current allocation policies often link the priority of paediatric patients to additional 
requirements (see Table 4) [10, 11, 19-23]. The new SOAS limits these requirements 
only to a blood group compatible donor aged < 60 years, resulting in an increased 
donor pool. Even if available organs are rejected, this permissive policy results in 
further offers within a short period of time, since physicians are free to decline 
transplants without further consequences. Moreover, the paediatric age limit for 
recipients after the new SOAS is < 20 years, independently of previous KTXs and 
therefore lies in the upper range compared to the majority of other countries, in 
which children are defined as being < 18 years old [21]. 
Estimated GFR is considered as the best indicator for renal function in children and 
adolescents [24]. Our data revealed significantly better eGFRs in children after the 
new SOAS for the 1 and 2 year outcome. With similar demographic and clinical 
characteristics for patients before and after the new SOAS, linear mixed model 
analysis showed that the new SOAS has a significant effect on renal function, even 
when baseline variables, which are possibly associated with graft failure or 
decreased graft function were adjusted for, such as HLA-mismatch, rejections and 
immunosuppressive treatment medication. Interestingly, only donor age was 
significantly different between both groups, with older kidney donors after the new 
SOAS, contrary to the widespread recommendation to prefer size-matched kidneys 
from younger patients [19, 25-27].  
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We found a significant decrease in time on dialysis for patients after the new SOAS, 
which seems to be mainly driven by the marked increase in pre-emptive KTX from 5 
to 34%. This increase can be traced back to the new SOAS, allowing unrestricted 
listing of patients with eGFRs < 15 ml/min per 1.73m2. The effectiveness of a priority 
policy for children should be mainly evaluated by changes in waiting time. This time 
span is highly variable for children throughout European countries, ranging from 
approximately 4 to 36 months, with a median of 11 months spent on the transplant 
list in 2008 [21]. Our data showed that the median time on the waiting list for children 
in Switzerland dropped from approximately 6 months to less than 3 months after the 
SOAS introduction. The new SOAS has decreased the time on dialysis to a point 
where about 97% of all children receive an organ within 4 years of RRT, as 
compared to only 76.9% in European countries in 2008 [28]. 
Improved graft outcomes can be achieved with pre-emptive KTX and it is therefore 
recommended, particularly in paediatric patients [29, 30]. The median prevalence of 
pre-emptive KTX among 29 European countries, however, was only around 17% in 
2008, which is comparable to the United States [21, 28, 31-33]. The increased rate 
after the new SOAS should result in overall improved long-term graft survival [34-36]. 
There has been an ongoing debate concerning the impact of HLA matching on the 
outcome of a renal transplant [37-42]. We have to acknowledge that we were not 
able to detect an effect on HLA-matching strategy after the policy change. The 
number of mismatches seen in our study is congruent with a current trend, which 
shows that about 90% of all deceased donor kidney-only transplantations have HLA 
mismatches to some extent [39, 43, 44] . However, HLA mismatch leads to a higher 
risk for a sensitised state in the presence of re-transplantation, which is associated 
with longer waiting times [41, 45, 46]. An optimized approach with less 
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histocompatibility mismatches should consequentially be preferred in future organ 
selection processes.  
While the proportion of our patients treated for high BP with at least one 
antihypertensive drug was unchanged in both groups, the UPC ratio was significantly 
decreased. Systolic hypertensive blood pressure (BP) as well as proteinuria are 
strong and independent predictive factors for graft survival in paediatric patients [47-
50]. CIT represents an independent risk factor for delayed graft function [51, 52]. As 
the kidney organs are retrieved and transplanted within a relatively small 
geographical area, resulting CITs were shown to be similar for the kidneys allocated 
before and after the new SOAS (median CIT between 8.25 and 8.0 hours) [53].  
Prioritising children in kidney allocation policies may raise concerns regarding 
medical and ethical issues leading to political discussions, because arguments in 
favour of adults may also be used [20]. This fact gains even more weight given the 
decreased living donor transplant rates in countries with a priority policy for children, 
as a direct consequence of more readily available deceased donor organs [33, 54, 
55]. Although the proportion of living donor grafts is still markedly higher in 
Switzerland compared to the median proportion (43%) among a total of 29 European 
countries, this trend is also visible in our data (65% vs. 48% living donor grafts) and 
will simultaneously aggravate the existing organ shortage [21, 22]. Then again, since 
children only encompass about 1-3% of all waitlisted patients, a shift in the graft 
source from living to deceased donors will not have an extensive effect on waiting 
times on the list for adult patients [2, 3]. Notwithstanding, an approach that involves 
encouraging living donations should still be pursued.  
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The main limitation of the current study is the retrospective design that clearly does 
not have the advantages of a prospective study, the small sample size limiting the 
evaluation of potential confounders for the observed eGFR improvement and the 
absence of long-term outcome data. Our findings, however, should be viewed as a 
preliminary assessment of the new SOAS and long-term effects of this policy will be 
reported. Although the working procedures and guidelines within Switzerland tend to 
be very uniform due to the relatively small geographic area, we cannot exclude that 
there was a change in the work-up process over time. In addition, there may be a 
selection bias of patients due to advances in treatment strategies in paediatric KTX 
[56]. 
 
CONCLUSION 
In conclusion, the findings of our study highlight the significant effects of the new 
SOAS, leading to an improved short-term clinical outcome of kidney transplants in 
children, increased number of pre-emptive deceased donor transplantations and 
reduced waiting times on list. Although the current study strengthens the arguments 
for prioritising children in renal transplantation, we still require further research to 
accumulate more evidence for these findings by assessing the effects of long-term 
graft survival.  
 
Figure Legend 
Figure 1. Kaplan-Meier plot of waiting time on the transplant list for children 
receiving a deceased donor allograft before and after the new SOAS. The log-rank 
comparison test showed a significantly decreased rate for children after the new 
SOAS (P=0.007). 
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Table 1. Recipient characteristics. Values are given as mean ± SD, median 
(min;max), or as absolute counts (percentage).  
  Before SOAS
(n=19) 
After SOAS
 (n=32) 
P-value 
Demographics 
Sex (female) 10 (53) 11 (34) 0.235 
Age at KTX – yrs  11.1 ± 4.7 10.7 ± 5.1 0.907 
Ethnicity 
 Caucasian 
 Middle East 
 Hispanic 
    Asian 
 
16 (84) 
1 (5) 
2 (11) 
0 (0)  
 
29 (91) 
1 (3) 
1 (3) 
1 (3) 
0.829 
Clinical characteristics    
Blood group 
 0  
 A  
 B  
 AB  
 
12 (63) 
7 (37) 
0 
0 
 
20 (65) 
10 (29) 
2 (6) 
0 
0.467 
Etiology of renal disease 
 CAKUT 
 hereditary 
 acquired 
 
6 (32) 
8 (42) 
5 (26) 
 
5 (16) 
12 (37) 
15 (47) 
0.384 
Mode of dialysis 
 HD  
 PD 
 
11 (58) 
7 (37) 
 
13 (41) 
8 (25) 
0.060 
Pre-transplant dialysis – days 555 (0;1715) 148 (0;3859) 0.006 
 
CAKUT, congenital anomalies of the kidney and urinary tract; HD, haemodialysis; 
PD, peritoneal dialysis; SOAS, Swiss Organ Allocation System; SD, standard 
deviation; KTX, kidney transplantation 
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Table 2. Donor and transplant characteristics. Values are given as mean ± SD, 
median (min;max), or as absolute counts (percentage).  
 Before SOAS
(n=19) 
After SOAS  
(n=32) 
P-value
Donor 
Age – yrs 23.0 ± 15.0 32.3 ± 15.4 0.040
Body Mass Index – kg/m2 24.7 (15.3;27.8) 24.2 (12.6;40.1) 0.961 
Cardiopulmonary reanimation 
duration – min 
0 (0;60) 0 (0;50) 0.980 
Support with catecholamines 13 (68) 22 (69) 0.980 
History of hypertension  2 (11) 0 (0) 0.061 
at KTX 
 Creatinine – µmol/l 
 Protein/creatinine>20 g/mol  
 C-reactive protein-mg/l 
 
76 (26; 148) 
5 (26) 
85.5 (5; 238) 
 
67 (38; 276) 
7 (22) 
99 (4; 534) 
 
0.316 
0.560 
0.444 
Diabetes mellitus 0 (0) 0 (0) – 
Death – cerebrovascular 
accident 
13 (68) 18 (56) 0.389 
Transplant 
Ethnicity match1 16 (84) 29 (91) 0.492
HLA mismatches  5 (2;6) 5 (3;6) 0.970
Cold ischemia time – min  495 (261; 1050) 476 (294; 971) 0.802 
Peak Panel Reactive Antibodies 
> 4% 
1 (5) 2 (6) 0.842 
Immunosuppressive treatment 
Induction therapy 
Maintenance therapy 
 CIN/AZA 
 CIN/MMF 
 
7 (37) 
 
3 (16) 
13 (68) 
 
14 (44) 
 
0 (0) 
31 (97) 
 
0.716 
0.013 
 
1
 all donors were of Caucasian ethnicity  
AZA, azathioprine; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; SOAS, 
Swiss Organ Allocation System; SD, standard deviation; KTX, kidney transplantation 
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1
 based on kidney biopsy either performed routinely or following clinical indication 
KTX, kidney transplantation; SOAS, Swiss Organ Allocation System; eGFR, 
estimated glomerular filtration rate; SD, standard deviation 
 
 
 
Table 4. Major characteristics of the Swiss Organ Allocation System (SOAS) 
in comparison to Eurotransplant and the Organ Procurement Transplantation 
Network (OPTN) USA for the allocation of deceased kidneys.  
 SOAS Eurotransplant OPTN 
Paediatric status < 20 yrs. < 16 yrs. < 18 yrs. 
 
Extended 
paediatric status 
⎯ • start of dialysis 
< 16 yrs. 
• registration on 
waiting list < 16 
yrs. (if dialysis 
started < 17 yrs.) 
• proof to be in 
maturation 
 
• listing regardless 
clinical criteria 
• start of dialysis < 
18 yrs. 
Paediatric bonus 
system 
• not applicable • extra 100 points 
• points for HLA 
mismatch doubled 
 
• age at match 
 
Table 3. Outcome measures.  Values are given as mean ± SD, median (min;max), or 
as absolute counts (percentage).  
 Before SOAS 
(n=19) 
After SOAS 
(n=32) 
P-value
Primary outcomes  
Renal function – ml/min per 1,73m2 
 eGFR 1 yr after KTX 
 eGFR 2 yrs after KTX 
 
67.8 ± 28.3 
65.3 ± 33.2 
 
91.9 ± 33.2 
91.0 ± 38.0 
 
0.013 
0.025 
Secondary outcomes
Protein/creatinine – g/mol 14.5 (0;477) 0 (0;94) 0.004
Hypertension medication 12 (63) 21 (66) 0.675
Waiting time on list – days 173 (9;1433) 76 (6;591) 0.021 
Pre-emptive KTX  1 (5) 11 (34) 0.018
Rejection1 6 (32) 9 (28) 0.804 
Living donor transplants – living / total 
(%) 
36/55 (65) 29/61 (48) 0.052 
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Pre-emptive KTX • yes  
(eGFR < 15) 
• yes, for high 
urgent cases only 
• no points for 
waiting time are 
accrued 
• possible 
 
 
Allocation 
algorithm criteria1 
child 
↓ 
adult 
AM2 
↓ 
HLA match 
↓ 
status paediatric 
↓ 
adult 
• combination of 
EPTS3 and KDPI-
scoring4 
 
1restricted to ABO-compatible recipients only 
2Acceptable mismatch program (adult/paediatric) to privilege highly sensitised 
transplant recipients  
3Estimated post-transplant survival (EPTS): Combining various recipient factors to 
summarise the need of a functioning kidney transplant based on a calculated score 
4Kidney donor profile index (KDPI): Combining various donor factors to summarise 
the risk of graft failure after kidney transplant based on a calculated score 
KTX, kidney transplantation; eGFR, estimated glomerular filtration rate in ml/min per 
1.73m2; HLA, human leucocyte antigen;  
 
 
 
 
